FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle Cell Lymphoma By Ogkologos - May 27, 2026 131 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BGB-11417-201 study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR Addressing Cancer Pain with Complementary Methods (Part 1) April 7, 2023 FDA Grants Accelerated Approval to Sotorasib for KRAS G12C-mutated NSCLC June 4, 2021 The Cancer Moonshot: Moving from Planning to Research November 19, 2018 Diagnosed With Breast Cancer At 24, Her Biggest Fear Wasn’t Death... October 10, 2019 Load more HOT NEWS Kid Friendly Meals A Painful Breast Lump May Be Mistaken For Cancer When It’s... Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of... What to Know About Getting Access to New Cancer Advances Presented...
